BriaCell Therapeutics Presents Evidence Of Strong Immune System Engagement And Anti-Cancer Activity Of Next-Gen Bria-OTS+ Platform In Preclinical Models At SITC Annual Meeting

Author: Benzinga Newsdesk | November 07, 2025 07:37am

• Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses
• Increased tumor cell cytotoxicity induced by both Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer)
• Preclinical data reinforces broad potential of Bria-OTS+ platform across multiple indications

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD.

Posted In: BCTX TSX:BCT